NodThera’s NLRP3 inhibitor NT-0796 reverses neuroinflammation in Parkinson’s Disease phase Ib/IIa trial. The positive data from its Phase Ib/IIa study indicates that NT-0796 reduces key neuroinflammatory and inflammatory biomarkers in Parkinson’s disease patients to the levels found in healthy elderly controls over 28 days.
The NLRP3 inflammasome is a main mediator of inflammation in many pathologies. NT-0796 selectively inhibits NLRP3, lowering levels of both pro-inflammatory cytokines IL-1β and IL-18. This action delivers therapeutic effects directly to immune cell types responsible for inflammatory diseases, including peripheral and neuroinflammatory diseases.